XTL

About XTL

XTL Biopharmaceuticals is an clinical-stage biotech company focused on autoimmune and neurological disorders. In January 2026, the company signed a binding agreement to acquire 85% of NeuroNOS, creating a specialized platform for autism and neuro-oncology with two FDA Orphan Drug designations.